Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

This study compares two chemotherapy combinations — irinotecan liposome or etoposide — each paired with an immunotherapy drug (adebrelimab) and carboplatin, as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), a fast-growing form of lung cancer that has spread at the time of diagnosis. **You may be eligible if...** - You have been diagnosed with extensive-stage small cell lung cancer confirmed by biopsy - You have not yet received systemic treatment for this cancer - You are between 18 and 70 years old in good general health (ECOG 0 or 1) - You have at least one measurable tumor lesion - Your heart, liver, kidney, and blood counts are within acceptable ranges **You may NOT be eligible if...** - You have already received chemotherapy or immunotherapy for this lung cancer - You are older than 70 or in poor general health - You have inadequate organ function Talk to your doctor to see if this trial is right for you.